Trial reportBMC anesthesiology2026
The effect of preoperative remimazolam application on emergence delirium in children under sevoflurane anesthesia based on electroencephalogram analysis: a randomized, double-blind, placebo-controlled study.
Trial report in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the effect of preoperative application of remimazolam on electroencephalogram (EEG) epileptiform discharges in children under sevoflurane anesthesia, and whether it can affect the incidence of emergence delirium (ED) by influencing epileptiform discharges.
methodsSixty-two children aged 1 to 6 years who were scheduled to undergo tonsillectomy or adenoidectomy under sevoflurane anesthesia were selected as the research subjects and randomly divided into the remimazolam group (Group R) and the control group (Group C), with 31 cases in each group. Group R received remimazolam (0.2 mg/kg IV bolus) 2 min before induction; Group C received equivalent normal saline. The primary outcome was the incidence of ED. The secondary outcomes were the incidence of EEG epileptiform activity during induction, the time from sevoflurane induction to the appearance of the first epileptiform discharge, the peak score of the Paediatric Anaesthesia Emergence Delirium (PAED), extubation time, changes in hemodynamic during induction, postoperative pain conditions and postoperative adverse events.
resultsThere was no significant difference in the incidence of ED between the two groups (P = 0.605), and there was no significant difference in the peak PAED score (P = 0.210). The application of remimazolam reduced the incidence of EEG epileptiform discharges in group R (P = 0.041) and prolonged the time of first epileptiform activity (P < 0.001). Patients in group R demonstrated better hemodynamic stability and well postoperative pain management. There was no significant difference between the two groups in terms of extubation time and postoperative adverse events during anesthesia emergence.
conclusionThe use of remimazolam before sevoflurane anesthesia reduced epileptiform EEG activity and improved hemodynamics during induction. However, it did not reduce the incidence of ED.
trial registrationChinese Clinical Trial Registry, ChiCTR2500104743(date:14/7/2025).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.